In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on uniQure NV (QURE – Research Report), with a price target of $60. The company’s shares closed on Friday at $29.88.
“Our $60 price target, is based on a 13-year DCF analysis that incorporates rNPV of two clinical-stage pipeline products AMT-061 and AMT-130. For AMT-061, we assume a 70% POS driven by the compelling clinical update, refer to our November 15, 2018, note for details, and anticipate commercial launch during 2H-2021, with a lower NAB-based exclusion of 5% vs. prior 10%, and model risk-adjusted peak sales of roughly $1.14B, during 2028.”
According to TipRanks.com, Chattopadhyay is ranked 0 out of 5 stars with an average return of -7.1% and a 38.2% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Autolus Therapeutics Plc, and Voyager Therapeutics Inc.
uniQure NV has an analyst consensus of Strong Buy, with a price target consensus of $62.33, representing a 108.6% upside. In a report issued on December 31, B.Riley FBR also initiated coverage with a Buy rating on the stock with a $72 price target.
The company has a one-year high of $43.23 and a one-year low of $16.77. Currently, uniQure NV has an average volume of 413.4K.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded on January 9, 2012 and is headquartered in Amsterdam, the Netherlands.